In response to an outbreak of 133,000 measles cases in 1996-1998 and to prevent an outbreak predicted for 2002, Romania conducted a nationwide measles-rubella vaccination campaign in October 1998. Some 2.1 million children aged 7-18 years were vaccinated. Data from national surveillance and seroprevalence studies conducted in three districts were used to assess the campaign and status of measles control. Surveillance data showed a dramatic drop in measles despite enhanced surveillance starting in October 1999. From October 1999 to December 2001, 400 suspected measles cases were reported, down from about 5000 cases annually in non-outbreak years. Only 29 (8%) of 386 cases with specimens were laboratory confirmed; 14 were clinically confirmed. Seroprevalence estimates showed high measles antibody levels before (92.9%) and after (94.4%) the campaign. The low number of laboratory-confirmed cases and high population immunity suggest that interruption of indigenous measles virus transmission is a real possibility for Romania.
introduction of a second dose of measles vaccine in 1995 [1, 2] . National surveillance data showed that cases occurred throughout the country, mostly in school-aged children who had received one dose of measles vaccine. Vaccine effectiveness studies conducted during the outbreak showed that Romanianproduced measles vaccine was about 90% effective and found no evidence of waning of vaccine-induced immunity [2] . In prior studies, high vaccination coverage with a single dose of a highly effective vaccine was not sufficient to prevent periodic measles outbreaks [3] [4] [5] [6] [7] . Mathematical modeling with Romania's measles vaccination coverage and surveillance data predicted the next measles epidemic in Romania would occur in 2002 and involve predominantly high school-aged children and young adults [8] .
To prevent future outbreaks and to achieve high population immunity with the aim of interrupting measles transmission, a mass measles and rubella immunization campaign was conducted beginning in October 1998 [9] . All children aged 7-14 years and boys aged 15-18 years lacking documentation of two doses of measles vaccine were targeted to receive measles vaccine (VVR-IC [Cantacuzino] or Rouvax [Pasteur Merieux]). All girls aged 15-18 years were targeted to receive measles-rubella vaccine (Eolarix [SmithKline Beecham]) to prevent future cases of congenital rubella syndrome. Prior to this campaign, there had been no use of rubella vaccine in the public sector. In all, 2.1 million children were vaccinated from October 1998 through January 1999. Here we describe recent measles surveillance information, results from a small measles seroprevalence study conducted before and after the mass vaccination campaign, and assess Romania's progress toward meeting the goal of the European Region of the World Health Organization (WHO) to eliminate measles by 2007 [10] .
METHODS
Enhanced measles surveillance. National measles surveillance data were reviewed and more detailed analysis was done for the period following the mass vaccination campaign (October 1999-December 2001). Beginning in October 1999, measles surveillance was enhanced by national and district-level training, introduction of a clinical case definition for suspected measles, and expansion of the notification requirement to include all suspected measles cases and the requirement that each suspected case have a serologic specimen taken for laboratory confirmation of measles infection.
A suspected measles case was defined as any person in whom a clinician suspected measles infection or a person with fever (138ЊC) and maculopapular rash and one or more symptoms of cough, coryza, or conjunctivitis. Laboratory confirmation of suspected cases was done at the Cantacuzino Institute, Bucharest, by using one of three commercial kits (Human, Novum, Dade Behring) that measure presence of measles IgM antibodies. If a suspected case was measles IgM negative, the case was not classified as measles and the sample was tested for rubella IgM antibodies. Suspected cases with a positive measles IgM test result were classified as laboratory-confirmed measles. A suspected case without a serologic specimen was classified as a clinically confirmed measles case. The 42 districts in Romania (including the capital city, Bucharest) report weekly to the national level, regardless of whether a suspected measles case is detected.
To monitor the quality and progress of the enhanced measles surveillance system, four surveillance indicators were measured: the proportion of suspected measles cases reported to the Ministry of Health within 7 days of rash onset; the proportion of cases with a serologic specimen taken within 27 days of rash onset; the proportion of cases that had specimens transported to the laboratory within 7 days of collection; and the proportion of cases that had IgM test results available within 7 days of receipt in the laboratory.
Seroprevalence study. Enrollment of participants took place before (31 August 1998-15 October 1998) and after (10 May 1999-10 July 1999) the mass vaccination campaign. Health care staff at 7 of 14 hospitals in 3 of the 42 districts requested participation of boys and girls aged 7-18 years who were seen for acute trauma or elective surgery that required a blood draw. Study participants answered questions from a questionnaire about demographic information and dates of prior measles vaccination. An extra 2 mL of blood was obtained at the time of venipuncture. Serum was separated and stored at Ϫ20ЊC. Specimens were transferred to Centers for Disease Control and Prevention for measles IgG antibody detection. Serologic results were analyzed in two strata, children aged 7-12 years and adolescents aged 13-18 years. The younger group has had an opportunity to receive two doses of measles vaccine prior to the mass campaign because of the second dose policy for children aged 7 years that started in 1994. Data were managed and analyzed with Epi Info software; statistical comparisons were made with x 2 tests [11] .
RESULTS

Enhanced measles surveillance.
In total, 400 suspected measles cases and 1 suspected measles-related death were reported from October 1999 to December 2001 (table 1) . Clinical and laboratory evidence indicated the death was not measles related. Among the 400 suspected cases, 386 (97%) had serologic specimens collected for laboratory confirmation. Of the 386 cases with specimens, 127 (33%), 250 (65%), and 6 (2%) were collected within 3, 3-27, and у28 days of rash onset, respectively (3 cases lacked the date of specimen collection). The 14 cases without specimens were classified as clinically confirmed measles. Of the suspected cases with specimens, 29 (8%) had measles IgM antibodies. Four additional cases with positive IgM ). There were no differences P ! .05 in the proportion of boys and girls enrolled in the study. Nearly 75% of participants came from urban areas. All districts had the same proportion of urban participants before and after the campaign. Reasons for hospital or clinic visit were mainly due to trauma or appendicitis and reasons did not vary significantly between districts or before and after the campaign.
Prevalence of measles antibodies was high in all age groups in the 3 districts surveyed and was high both before (92.9%) and after (94.4%) the immunization campaign (table 4). One of the 3 districts showed a significant increase in measles antibody prevalence among the age group (13-18 years) not covered by the second measles dose policy.
Coverage with two doses of measles vaccine significantly in- [12, 13] .
In Romania from October 1999 through December 2001, no epidemiologic links were identified among the confirmed measles cases. Possible reasons include inadequate case finding around confirmed measles cases; no, or limited spread from imported measles cases; or false-positive IgM test results. The clusters of laboratory-confirmed cases in Bucharest (8 cases and 2 cases), Mehedinti (2 cases), and Timisoara (2 cases) suggest small outbreaks and underscore the need for contact investigations for confirmed measles cases. Although Romania has the laboratory capacity to isolate measles virus from clinical specimens, no isolations have been made since the end of the 1996-1998 outbreak, mainly due to difficulty in obtaining and transporting specimens required for isolation. Genotypic information on confirmed cases is needed to determine if confirmed cases are due to indigenous or imported measles virus and to determine if they share chains of transmission.
Enhanced measles surveillance has been successfully implemented in Romania: Indicators approach or achieve the target of у80%. However, reporting cases within 7 days of rash onset and decreasing specimen transport time are areas that need improvement. The latter is particularly troublesome in remote districts with infrequent road or rail connections to Bucharest where the national laboratory is located. The percentage of cases with serologic specimens has been consistently high (195%). Cases without serologic specimens were classified as clinically confirmed measles to identify areas requiring improvement in surveillance. The 3%-4% of suspect cases that were clinically confirmed during 1999-2001 was similar to results from the WHO Americas Region where 5%-6% of cases were clinically confirmed in 2000-2001 [14] [15] [16] .
In Romania, young adults may have higher susceptibility to measles than either school-aged children or older adults. Surveillance data show about one quarter of laboratory-confirmed cases are 118 years old. The seroprevalence survey found variable measles immunity and two-dose measles vaccination coverage of !90% among the oldest age cohorts (16-18 years). These persons were born and grew up in the early years of the measles vaccination program when coverage was lower and disease transmission was declining, thereby reducing their chance of acquiring immunity to measles. Romania may have a similar susceptibility pattern to that of Brazil prior to the 1997 outbreak. This large measles outbreak occurred mainly in São Paulo and included numerous young adults who were not vaccinated against measles as children or during mass campaigns and who missed exposure to wild measles virus [14] . A similar pattern of moderate susceptibility among young adults has been found in the United States [17] .
In Romania, young adults not enrolled in school are difficult to reach for immunization opportunities. Bucharest was well prepared for the 1998-1999 mass immunization campaign and performed well among the in-school population; however, reaching persons out of school proved to be difficult as the coverage was only 25% by a census-based coverage estimate [9] . Results from the post-campaign survey showed that the two-dose coverage among those aged 13-18 years from Bucharest was only 70%. Itinerate persons and communities in both rural and urban setting are also considered difficult to reach as part of routine or supplemental immunization strategies.
Results from three districts indicate that seroprevalence prior to the campaign was high, probably due to both high immunization coverage among the younger cohorts and the large 1996-1998 measles outbreak that largely affected teenagers [2] . The study also showed that the effect of the campaign probably varied across the country by quality of implementation and the proportion of the population enrolled in school. The campaign goal was to reduce susceptibility levels to р5% among the cohorts targeted as recommended by the WHO European Region as a means to achieve elimination of indigenous measles transmission in the region by 2007 [10] . Other studies indicate that population immunity should be у94% to achieve elimination [18, 19] . If findings from the three districts represent the experience of the rest of the country, Romania may have achieved this goal at a national level and may be close at the district level.
The challenge remains to further strengthen measles surveillance, including active case finding and virus isolation, to maintain high levels of routine immunization coverage, and to address immunity gaps by taking advantage of opportunities to immunize groups thought to remain at risk. These include children of itinerant parents (i.e., gypsy children), health care workers, or young adults not attending school who may have missed a second dose of measles vaccine.
